
Paros Bio · Boston
Gene therapy for neurodegenerative diseases
A gene replacement approach to treat Autosomal Dominant Alzheimer’s Disease (ADAD).
The problem
Rare, genetic, and unambiguous
While the vast majority of Alzheimer’s disease is sporadic in nature with unknown etiology, there are rare genetic forms — autosomal dominant Alzheimer’s disease, ADAD.
The most common form is caused by loss-of-function mutations in the presenilin 1 gene (PSEN1). Paros Bio is creating a gene therapy to treat ADAD caused by mutations in PSEN1, that will directly address the underlying genetic cause of this disease.
The company anticipates that this novel approach will be a first-in-class treatment for ADAD, with the potential to slow or halt the progression of this devastating disease.
A genetic approach
Replace the mutant gene
ADAD is caused by mutations in one of three genes, with PSEN1 accounting for 70–80% of cases. The lead programme focuses on patients harbouring PSEN1 mutations and seeks to introduce an AAV gene therapy vector expressing a wildtype PSEN1 gene to replace the mutant form found in ADAD patients.